Evox Therapeutics Ltd has appointed Edwin Moses as non-executive chairman of the board of directors as it advances its technology for using exosomes to deliver drugs. Dr Moses was previously chief executive of Ablynx NV which was acquired by Sanofi SA in 2018. Prior to this he was CEO of Oxford Asymmetry International and oversaw the merger of that company with Evotec AG in 2000. Dr Moses has more than 25 years of board level experience with more than 10 European life science companies.
Evox Therapeutics announced the appointment on 20 December 2018.
Copyright 2019 Evernow Publishing Ltd